Drug Profile
Latanoprost insert
Alternative Names: Eye-D® latanoprost insert; Subconjunctival latanoprost controlled release insert; VS 101 insertLatest Information Update: 16 Feb 2023
Price :
$50
*
At a glance
- Originator ViSci
- Class Antiglaucomas; Prostaglandins; Small molecules
- Mechanism of Action Prostaglandin F2 alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Glaucoma
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for preclinical development in Glaucoma in Israel (Subconjunctival, Implant)
- 24 Jul 2017 Efficacy data from a phase I/IIb trial in Glaucoma released by BioLight Life Sciences
- 07 Sep 2016 Latanoprost insert is still in phase I/II trials for Glaucoma in USA (Subconjunctival)